483s and Warning Letters Point to Inadequate Quality Oversight
Ajay Babu Pazhayatil
Advertisement
Ajay Pazhayattil is a management consultant. ([email protected]). He has held key management roles with brand name, generic, and contract manufacturing pharmaceutical organizations.
Articles by Ajay Babu Pazhayatil
Production and process controls, organization and personnel were the top problems found, while packaging and labelling citations increased in 2017 and 2018.
Advertisement
Latest Updated Articles
Lessons from FDA 483s and cGMP Inspection DataOctober 2nd 2019
- Solving Pharma’s Quality Unit Identity Crisis
July 2nd 2020
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Is Compliant AI in Pharma Even Possible? The Search for an Honest Answer
2
What's Driving Biopharma M&A Strategy in 2026
3
Reimagining Signal Management: How Autonomous Pharmacovigilance Could Render Reporting Timelines a Thing of the Past
4
Implications of FDA Granting Priority Review to AZ's Ravulizumab
5